« Scientist Shortage? The Media Starts to Catch On. |
| Employee Surveillance at the FDA »
July 16, 2012
AstraZeneca Admits It Spent Too Much Money
Looks like AstraZeneca's internal numbers agree with Matthew Herper's. The company was talking about its current R&D late last week, and this comment stands out:
Discovery head Mene Pangalos told reporters on Thursday that mistakes had been in the past by encouraging quantity over quality in early drug selection.
"If you looked at our output in terms of numbers of candidates entering the clinic, we were one of the most productive companies in the world, dollar for dollar. If you rated us by how many drugs we launched, we were one of the least successful," he said.
Yep, sending compounds to the clinic is easy - you just declare them to be Clinical Candidates, and the job is done. Getting them through the clinic, now, that's harder, because at that point you're encountering things that can't be rah-rah-ed. Viruses and bacteria, neurons and receptors and tumor cells, they don't care so much about your goals statement and your Corporate Commitment to Excellence. In the end, that's one of the things I like most about research: the real world has the last laugh.
The news aggregator Biospace has a particularly misleading headline on all this: "AstraZeneca Claims Neuroscience Shake-Up is Paying Off ; May Advance at Least 8 Drugs to Final Tests by 2015". I can't find anyone from AZ putting it in quite those terms, fortunately. That would be like saying that my decision, back in Boston, to cut costs by not filling my gas tank is paying off as I approach Philadelphia.
+ TrackBacks (0) | Category: Business and Markets | Clinical Trials | Drug Development
POST A COMMENT
- RELATED ENTRIES
- Research Fraud, From A Master Fraud Artist
- The Portable Chemist's Consultant
- More Single-Cell Magnetic Imaging
- Towards Better Papers, With Real Results in Them
- What The Heck Does "Epigenetic" Mean, Anyway?
- A New Book on Longevity Research
- Watching PARP1 Inhibitors Fail To Work, Cell By Cell
- IBM And The Limits of Transferable Tech Expertise